ES2098496T3 - Forma medicamentosa aplicable por via peroral para el tratamiento de estados de insuficiencia de dopamina en el sistema nervioso central. - Google Patents

Forma medicamentosa aplicable por via peroral para el tratamiento de estados de insuficiencia de dopamina en el sistema nervioso central.

Info

Publication number
ES2098496T3
ES2098496T3 ES92903405T ES92903405T ES2098496T3 ES 2098496 T3 ES2098496 T3 ES 2098496T3 ES 92903405 T ES92903405 T ES 92903405T ES 92903405 T ES92903405 T ES 92903405T ES 2098496 T3 ES2098496 T3 ES 2098496T3
Authority
ES
Spain
Prior art keywords
weight
pct
parts
treatment
peroral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92903405T
Other languages
English (en)
Inventor
Udo Prof Dr Wenzel
Guenther Dipl Ing Weber
Juergen Dr Metzner
Alfred Dr Daerr
Sabine Dr Freitag
Frank-Ulrich Dr Floether
Frank-Michael Albert
Margit Dr Haase
Edith Leistner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Puren Pharma GmbH and Co KG
Original Assignee
Isis Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharma GmbH filed Critical Isis Pharma GmbH
Application granted granted Critical
Publication of ES2098496T3 publication Critical patent/ES2098496T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

LA INVENCION SE REFIERE A UNA FORMULACION MEDICINAL APLICABLE POR VIA ORAL, ASI COMO UN PROCEDIMIENTO PARA SU OBTENCION EN LA QUE LA MATERIA MEDICINAL LEVIDOPA O CARBIDOPA EN UNA BASE HIDROFILA CON RELACIONES DEFINIDAS SE EMBEBE EN UNA MEZCLA DE SUSTANCIAS AUXILIARES NO TOXICAS Y CONTENIDOS DE ACETATO DE VINILO DIFERENTES DE POLIVINILOALCOHOLES: SE AMPLIA ESENCIALMENTE LA POSIBILIDAD DE LA TERAPIA DEL ESTADO BASICO DE CARENCIA DE DOPAMINA O PARKISON MORBUS, Y PARTICULARMENTE GARANTIZA EL NIVEL DE SANGRE EFECTIVO Y TERAPEUTICO EN LA FASE FLUIDA.
ES92903405T 1991-01-23 1992-01-23 Forma medicamentosa aplicable por via peroral para el tratamiento de estados de insuficiencia de dopamina en el sistema nervioso central. Expired - Lifetime ES2098496T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4101873A DE4101873C2 (de) 1991-01-23 1991-01-23 Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände

Publications (1)

Publication Number Publication Date
ES2098496T3 true ES2098496T3 (es) 1997-05-01

Family

ID=6423528

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92903405T Expired - Lifetime ES2098496T3 (es) 1991-01-23 1992-01-23 Forma medicamentosa aplicable por via peroral para el tratamiento de estados de insuficiencia de dopamina en el sistema nervioso central.

Country Status (22)

Country Link
US (1) US5532274A (es)
EP (1) EP0568577B1 (es)
JP (1) JP3382940B2 (es)
AT (1) ATE147264T1 (es)
AU (1) AU658171B2 (es)
BG (1) BG61677B1 (es)
CA (1) CA2101164C (es)
CZ (1) CZ280847B6 (es)
DE (2) DE4101873C2 (es)
DK (1) DK0568577T3 (es)
EE (1) EE03016B1 (es)
ES (1) ES2098496T3 (es)
FI (1) FI101040B (es)
GR (1) GR3022993T3 (es)
LT (1) LT3659B (es)
LV (1) LV11103B (es)
NO (1) NO304638B1 (es)
RO (1) RO114737B1 (es)
RU (1) RU2114619C1 (es)
SK (1) SK369292A3 (es)
UA (1) UA27848C2 (es)
WO (1) WO1992012710A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756056B2 (en) * 1997-04-08 2004-06-29 Alan A. Rubin Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US6531153B2 (en) 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
BR0212951A (pt) * 2001-09-28 2004-10-26 Mcneil Ppc Inc Formas de dosagens compósitas
JP2006506362A (ja) * 2002-10-11 2006-02-23 デポメド・ディベロップメント・リミテッド 胃内保持型レボドパデリバリー形態
ES2360759T3 (es) * 2003-08-29 2011-06-08 Centocor Ortho Biotech Inc. Composiciones farmacéuticas y procedimiento de utilización de la levodopa y de la carbidopa.
EP1670450B8 (en) * 2003-08-29 2011-03-23 Centocor Ortho Biotech Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
US8815950B2 (en) * 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
RU2440100C2 (ru) * 2005-03-28 2012-01-20 Орексо Аб Новые фармацевтические композиции, полезные в лечении болезни паркинсона
US20080299204A1 (en) * 2005-06-23 2008-12-04 Spherics, Inc. Dosage forms for movement disorder treatment
US20070275060A1 (en) * 2005-08-05 2007-11-29 Osmotica Costa Rica Sociedad Anonima Extended release solid pharmaceutical composition containing carbidopa and levodopa
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
WO2008079404A2 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
KR101752080B1 (ko) 2007-12-28 2017-06-28 임팩스 라보라토리즈, 인코포레이티드 레보도파 방출 제어형 제제 및 이의 용도
EP2233131A1 (en) * 2009-03-23 2010-09-29 Laboratorios Lesvi, S.L. Pharmaceutical composition containing levodopa, entacapone and carbidopa
KR20130009553A (ko) * 2011-07-15 2013-01-23 한미약품 주식회사 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제
EP3054929B1 (en) 2013-10-07 2020-08-05 Impax Laboratories, LLC Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
JP7066351B2 (ja) * 2017-08-18 2022-05-13 大原薬品工業株式会社 良好な徐放性を有する、レボドパ含有小型化錠剤
JP6695013B1 (ja) * 2018-11-13 2020-05-20 日本酢ビ・ポバール株式会社 結合剤
US20210324222A1 (en) * 2018-11-13 2021-10-21 Japan Vam & Poval Co., Ltd. Binder
JP6694564B1 (ja) * 2018-11-13 2020-05-13 日本酢ビ・ポバール株式会社 結合剤
CN112955136A (zh) * 2018-11-13 2021-06-11 日本瓦姆&珀巴尔株式会社 粘结剂
CN115397469A (zh) * 2020-04-10 2022-11-25 日本瓦姆&珀巴尔株式会社 粘合剂

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE631201C (de) * 1932-08-07 1936-06-16 Chemische Forschungs Gmbh Traegerstoff fuer Arzneimittel
DE748317C (de) * 1941-08-17 1944-12-19 Wacker Chemie Gmbh Verfahren zur Herstellung in Wasser zerfallender Faeden, Filme, Baender, Schlaeuche u. dgl. aus unvollstaendig verseiften Polyvinylalkoholen
US3584113A (en) * 1967-08-31 1971-06-08 Eisai Co Ltd Process for the production of medical preparations having sustained release of therapeutical effect
NL149372B (nl) * 1968-10-01 1976-05-17 Merck & Co Inc Werkwijze voor het bereiden van farmaceutische preparaten, alsmede de door toepassing daarvan verkregen gevormde voortbrengselen.
US3769424A (en) * 1970-10-01 1973-10-30 Merck & Co Inc Composition and method of treating dopamine deficiency in brain tissue
IE49522B1 (en) 1979-04-26 1985-10-16 Merrell Toraude & Co Alpha-halomethylaminoacids
DE3042916A1 (de) * 1979-06-01 1982-07-01 Joachim 7440 Nürtingen Dudzik Tablette
CA1218604A (en) * 1981-07-08 1987-03-03 Alec D. Keith Trinitroglycerol sustained release vehicles and preparations therefrom
US4424235A (en) * 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
CH652025A5 (de) * 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
JPS5852219A (ja) * 1981-09-22 1983-03-28 Sumitomo Chem Co Ltd パ−キンソン病治療剤
EP0147780A3 (en) * 1984-01-03 1987-03-11 Merck & Co. Inc. Drug delivery device
US4927633A (en) * 1984-03-19 1990-05-22 Alza Corporation Dispenser for delivering drug to livestock
US4685918A (en) * 1985-02-01 1987-08-11 Merck & Co., Inc. Lipid osmotic pump
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
ZA889189B (en) * 1986-06-16 1989-08-30 Merck & Co Inc Controlled release combination of carbidopa/levodopa
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
US4892778A (en) * 1987-05-27 1990-01-09 Alza Corporation Juxtaposed laminated arrangement
US4940465A (en) * 1987-05-27 1990-07-10 Felix Theeuwes Dispenser comprising displaceable matrix with solid state properties
US4915949A (en) * 1987-07-13 1990-04-10 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
CA1331563C (en) * 1987-08-03 1994-08-23 Gaylen M. Zentner Device for the controlled release of drugs with donnan-like modulation by charged insoluble resins
US4946686A (en) * 1987-09-24 1990-08-07 Merck & Co., Inc. Solubility modulated drug delivery system
AU608891B2 (en) * 1987-09-24 1991-04-18 Merck & Co., Inc. Solubility modulated drug delivery device
DE3875716D1 (de) * 1987-12-31 1992-12-10 Asta Medica Ag Synergistische kombination von decarboxylasehemmern und l-dopa-pellets.
DE3841955A1 (de) * 1987-12-31 1989-07-13 Asta Pharma Ag Synergistische kombination von decarboxylasehemmern und l-dopa-pellets

Also Published As

Publication number Publication date
UA27848C2 (uk) 2000-10-16
DE4101873A1 (de) 1992-07-30
DE59207852D1 (de) 1997-02-20
CA2101164A1 (fr) 1992-07-24
BG61677B1 (bg) 1998-03-31
WO1992012710A1 (de) 1992-08-06
AU658171B2 (en) 1995-04-06
FI933304A (fi) 1993-07-22
EE03016B1 (et) 1997-08-15
SK278736B6 (sk) 1998-02-04
CZ280847B6 (cs) 1996-04-17
NO304638B1 (no) 1999-01-25
US5532274A (en) 1996-07-02
RO114737B1 (ro) 1999-07-30
FI101040B (fi) 1998-04-15
ATE147264T1 (de) 1997-01-15
FI933304A0 (fi) 1993-07-22
RU2114619C1 (ru) 1998-07-10
DE4101873C2 (de) 1993-12-09
NO932522D0 (no) 1993-07-09
CZ369292A3 (en) 1993-09-15
LT3659B (en) 1996-01-25
NO932522L (no) 1993-07-09
JP3382940B2 (ja) 2003-03-04
JPH06504543A (ja) 1994-05-26
BG97894A (bg) 1994-04-29
DK0568577T3 (da) 1997-06-30
AU1186892A (en) 1992-08-27
LV11103B (en) 1996-06-20
LV11103A (lv) 1996-04-20
EP0568577A1 (de) 1993-11-10
LTIP555A (en) 1994-11-25
CA2101164C (fr) 2001-04-24
GR3022993T3 (en) 1997-07-30
EP0568577B1 (de) 1997-01-08
SK369292A3 (en) 1998-02-04

Similar Documents

Publication Publication Date Title
ES2098496T3 (es) Forma medicamentosa aplicable por via peroral para el tratamiento de estados de insuficiencia de dopamina en el sistema nervioso central.
AR028299A1 (es) Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
KR920702216A (ko) 아세틸 d-카르니틴의 녹내장 치료에의 용도
AR037081A1 (es) Composicion para el suministro transdermico de fentanilo
CY1105120T1 (el) Η αντιμετωπιση αναπνευστικων νοσων
KR880000098A (ko) 콘드로이틴 설페이트 면역자극 조성물
DK1741426T3 (da) Smelteekstruderede oralt administrerbare hydromorphonformuleringer
BR0011116A (pt) Usos de uma nsaid que libera no como um sal farmaceuticamente aceitável ou um enanciÈmero do mesmo, e de uma nsaid que libera no e de um inibidor de bomba de próton suscetìvel a ácido ou um sal do mesmo ou um enanciÈmero ou de um sal do enanciÈmero, método para o tratamento de uma infecção bacteriana, e, formulação farmacêutica adequada para uso no tratamento de infecções bacterianas
ES2130622T3 (es) Sistema para la administracion transdermica de farmacos.
DK0586621T3 (da) Linsidomin til behandling af erektile dysfunktioner
ES2092890T3 (es) Aplicacion del riluzol en el tratamiento de la enfermedad de parkinson y de los sindromes de parkinson.
NO992944L (no) Virkestoffbµrer for avgivelse av apomorfin i munnhulen
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
ATE315399T1 (de) Hemmung von systemischen infektionen in menschen und wirbeltieren mit ballaststoffen
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
KR970025615A (ko) 암 전이 억제제
KR900007424A (ko) 세포보호성 약제로서의 n-아세틸글루코사민의 사용방법 및 그 조성물
AR026254A1 (es) El uso de una preparacion de liberacion controlada para la preparacion de un medicamento para aumentar la dosis o la exposicion sistemica de un farmaco queinhibe la fosfodiesterasa 4
FI955837A0 (fi) Menetelmä suun kautta annettavan, kiinteän, diklofenaakkia sisältävän annostelumuodon valmistamiseksi
KR920019350A (ko) 자기면역질환요법을 위한 약제조성물
FR2662942B1 (fr) Medicament immunostimulant a base de glycopeptidolipides polaires de mycobacterium chelonae.
Boesen et al. Bactericidal activity by sub-agglutinating levels of rainbow trout( Oncorhynchus mykiss) antiserum to Vibrio anguillarum serogroup O 1
ES2139774T3 (es) Uso de una combinacion de antineoplastones en la preparacion de un medicamento para el tratamiento de la neurofibromatosis.
AR007059A1 (es) Uso de interferon en la preparacion de medicamentos y composiciones via oromucosal o por contacto
KR890007728A (ko) 진통제 제조방법

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 568577

Country of ref document: ES